Uingereza - Kiingereza - VMD (Veterinary Medicines Directorate)

ecuphar veterinaria s.l.u. - suxibuzone - granules - anti inflammatory nsaid - horses

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

indivior europe limited - buprenorphine, naloxone - opioid-related disorders - other nervous system drugs - substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse. treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine; naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone - sublingual tablet - 2mg/0.5mg - active: buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone excipient: acesulfame potassium citric acid lactose monohydrate lemon flavour phs-020484 magnesium stearate maize starch mannitol povidone sodium citrate dihydrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included in suboxone to deter intravenous misuse of the product.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 8.64mg equivalent to 8 mg buprenorphine; naloxone hydrochloride dihydrate 2.44mg equivalent to 2 mg naloxone - sublingual tablet - 8mg/2mg - active: buprenorphine hydrochloride 8.64mg equivalent to 8 mg buprenorphine naloxone hydrochloride dihydrate 2.44mg equivalent to 2 mg naloxone excipient: acesulfame potassium citric acid lactose monohydrate lemon flavour phs-020484 magnesium stearate maize starch mannitol povidone sodium citrate dihydrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included in suboxone to deter intravenous misuse of the product.

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - buprenorphine hydrochloride 2 mg - suboxone and subutex are indicated for the treatment of opioid dependence. suboxone and subutex should not be administered to patients who have been shown to be hypersensitive to buprenorphine, and suboxone should not be administered to patients who have been shown to be hypersensitive to naloxone. suboxone and subutex are controlled as schedule iii narcotics under the controlled substances act. buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces dependence of the opioid type, characterized by moderate withdrawal upon abrupt discontinuation or rapid taper. the withdrawal syndrome is milder than seen with full agonists, and may be delayed in onset (see warnings) neonatal withdrawal has been reported in the infants of women treated with subutex during pregnancy (see precautions) suboxone contains naloxone and if misused parenterally, is highly likely to produce marked and intense withdrawal symptoms in subjects dependent on other opioid agonists.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

reckitt benckiser pty ltd - naloxone hydrochloride; buprenorphine hydrochloride -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - naloxone hydrochloride dihydrate, quantity: 2.44 mg (equivalent: naloxone, qty 2 mg); buprenorphine hydrochloride, quantity: 8.64 mg (equivalent: buprenorphine, qty 8 mg) - soluble film - excipient ingredients: acesulfame potassium; maltitol; polyethylene oxide; citric acid; sunset yellow fcf; hypromellose; sodium citrate; titanium dioxide; propylene glycol; purified water; industrial methylated spirit; flavour - for the treatment of opiate dependence within a framework of medical, social, and psychological treatment.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 2.16 mg (equivalent: buprenorphine, qty 2 mg); naloxone hydrochloride dihydrate, quantity: 0.61 mg (equivalent: naloxone, qty 0.5 mg) - soluble film - excipient ingredients: sunset yellow fcf; polyethylene oxide; hypromellose; maltitol; citric acid; acesulfame potassium; sodium citrate; titanium dioxide; propylene glycol; purified water; industrial methylated spirit; flavour - for the treatment of opiate dependence within a framework of medical, social, and psychological treatment.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 12.96mg equivalent to 12 mg buprenorphine; naloxone hydrochloride dihydrate 3.66mg equivalent to 3 mg naloxone;   - wafer - active: buprenorphine hydrochloride 12.96mg equivalent to 12 mg buprenorphine naloxone hydrochloride dihydrate 3.66mg equivalent to 3 mg naloxone   excipient: acesulfame potassium citric acid hypromellose e-15 maltitol natural lime flavour (3000180) opacode white ns-78-18007 polyethylene oxide sodium citrate sunset yellow fcf - treatment of opioid dependence, within a framework of medical, social and psychological treatment.